Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:54 PM ET 10-Q
Financial Results Private Bancorp of America, Inc. PBAM

Private Bancorp of America Q3 2026 Results: Net Income $11.4M, Up 17.6% YoY

Private Bancorp of America, Inc. reported net income of $36.6 million for the nine months ended September 30, 2026, an increase from $30.7 million in the prior year period. Total assets grew to $2.75 billion, driven by increases in cash equivalents and debt securities, while net interest income improved significantly due to higher interest and fees on loans.

Key figure
Net income $11.4M · +17.6% YoY
4:52 PM ET 8-K
Financial Results Spruce Power Holding Corp SPRU

Spruce Power Holding Financial Results

Spruce Power reported third quarter 2026 financial results, achieving net income of $6.0 million compared to a net loss in the prior year period. The company highlighted a 23% year-over-year reduction in SG&A expenses driven by streamlining efforts and the use of AI in operations, contributing to a 52% increase in Adjusted Cash Flow from Operations.

Term
Q3 2026

“Our third quarter 2026 results reflect continued cost discipline and steady operational execution. Most importantly, subsequent to quarter end we met the October 30 milestone by executing a non-binding term sheet for the refinancing of SP1, SP2, and SP3. Meeting this important milestone extended the maturity of the SP1 facility to January 30, 2027.”

Chris Hayes, Chief Executive Officer

“During the quarter we continued to see the positive effects of the streamlining efforts we implemented last fall. SG&A expenses were reduced by 23% compared to last year, reflecting both the structural efficiencies we have built into the operating model and the aggressive new programs to implement labor savings across our operational functions through the targeted use of AI.”

Chris Hayes, Chief Executive Officer
4:52 PM ET 10-Q
Financial Results 1st Franklin Financial Corp

1st Franklin Financial Q3 2026 Results: Net Income $7.56M, Up 22.3% YoY

1st Franklin Financial Corp reported net income of $19.1 million for the nine months ended September 30, 2026, a significant increase from $12.1 million in the prior year period. Total assets grew slightly to $1.47 billion, while the company experienced a notable increase in interest income and a higher provision for credit losses.

Key figure
Net income $7.56M · +22.3% YoY
4:51 PM ET 10-Q
Financial Results KinderCare Learning Companies, Inc. KLC ▶ Call

KinderCare Learning Companies Q3 2026 Results: Net Loss of $85M

KinderCare Learning Companies reported a significant net loss of $383.6 million for the nine months ended October 3, 2026, primarily driven by $401.2 million in impairment losses. Revenue remained relatively flat year-over-year at approximately $2.04 billion, while total shareholders' equity decreased from $755.3 million to $385.0 million during the period.

Key figure
Net loss $85M
4:49 PM ET 10-Q
Financial Results TMC the metals Co Inc. TMC

TMC the metals Co Q3 2026 Results: Net Loss of $28.4M, Loss Narrows

TMC the metals company Inc. reported a significant increase in exploration and evaluation expenses to $92.9 million for the nine months ended September 30, 2026, compared to $29.6 million in the prior year. The company recorded a net operating loss of $138.7 million for the same period, while its cash position decreased to $79.3 million from $117.6 million at year-end 2025.

Key figure
Net loss $28.4M
4:47 PM ET 10-Q
Financial Results First Eagle Private Credit Fund

First Eagle Private Credit Fund Q3 2026 Results: Net Income $4.27M, Down 62.0% YoY

First Eagle Private Credit Fund reported total non-controlled/non-affiliated investments at a fair value of $526.5 million as of September 30, 2026, a decrease from $567.3 million at year-end 2025. The fund maintained $38.5 million in cash and cash equivalents and reported 12,844,156 Class I shares outstanding as of November 12, 2026.

Key figure
Net income $4.27M · -62.0% YoY
4:46 PM ET 10-Q
Financial Results Marblegate Capital Corp MGTE

Marblegate Capital Q3 2026 Results: Net Loss of $3.15M, Loss Widens

Marblegate Capital Corp reported a net loss of $9.8 million for the nine months ended September 30, 2026, compared to a $52.3 million loss in the prior year period. While total revenue grew to $47.2 million driven by fleet operations, the company faced increased operating expenses and net losses on loans held for investment.

Key figure
Net loss $3.15M
4:46 PM ET 10-Q
Financial Results Andalusian Credit Company, LLC

Andalusian Credit Company Q3 2026 Results: Net Income $4.04M, Up 62.7% YoY

For the nine months ended September 30, 2026, Andalusian Credit Company, LLC reported total investment income of $30.5 million and net investment income of $13.2 million. Total net assets grew to $417.5 million, driven by $71.1 million in share issuance proceeds, while the net asset value per share increased slightly to $15.33.

Key figure
Net income $4.04M · +62.7% YoY
4:46 PM ET 8-K
Financial Results InspireMD, Inc. NSPR

InspireMD Financial Results

InspireMD reported third quarter 2026 financial results, highlighted by total revenue of $2.2 million, a 9% increase year-over-year driven by international performance. During the quarter, the company received FDA approval for its CGuard Prime carotid stent system for TCAR procedures, which is expected to double its U.S. addressable market with a commercial launch planned for Q4 2026.

Term
Q3 2026

“FDA approval of CGuard Prime for TCAR procedures represents a transformative milestone for InspireMD, enabling the launch of our next-g”

Marvin Slosman, Chief Executive Officer
4:46 PM ET 10-Q
Financial Results Bio Green Med Solution, Inc. BGMS

Bio Green Med Solution Q3 2026 Results: Net Loss of $449K, Loss Narrows

Bio Green Med Solution, Inc. is undergoing a significant business combination with Future NRG Sdn. Bhd. (FNRG), which will result in FNRG shareholders owning over 99% of the combined company. The company recently deconsolidated its former subsidiary, Cyclacel Limited, following a creditors voluntary liquidation and has pivoted its business focus through various asset sales and exchange agreements.

Key figure
Net loss $449K
4:46 PM ET 8-K
Financial Results Aeluma, Inc. ALMU

Aeluma Financial Results

Aeluma reported Q1 fiscal 2027 financial results with revenue of $0.6M and a net loss of $3.8M. The company highlighted a new purchase agreement with Aixtron for MOCVD manufacturing expansion and ongoing negotiations for $30M in CHIPS Act funding.

Term
Q1 2027

“The current U.S. AI infrastructure buildout continues to progress and is expected to reach an aggregate investment of $10.3 trillion in 2032. The opportunities for photonics are vast, spanning scale-up and scale-out AI architectures in data centers.”

Jonathan Klamkin, Ph.D., Founder and CEO

“As we progress through fiscal 2027, we remain focused on technology and product development for AI Datacom opportunities. Aeluma’s high-speed photodetectors and quantum dot lasers continue to attract customer attention.”

Jonathan Klamkin, Ph.D., Founder and CEO
4:46 PM ET 8-K
Financial Results Sutro Biopharma, Inc. STRO

Sutro Biopharma Financial Results

Sutro Biopharma reported third quarter 2026 financial results, highlighting a cash position of $142.2 million which is expected to fund operations into the first half of 2028. The company advanced its clinical pipeline with the first patient dosed in the STRO-006 Phase 1 study and reported progress on its STRO-004 and STRO-227 ADC programs.

Term
3 months

“Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic in less than a year, and our dual-payload ADC, STRO-227, expected to follow in early 2027.”

Jane Chung, Chief Executive Officer of Sutro

“Early data from STRO-004 give us confidence in its potential to deliver meaningful clinical benefit with our proprietary ADC platform. In addition, our collaboration partner Astellas has initiated patient dosing with a second dual-payload immunostimulatory ADC, further highlighting our strong execution and ability to deliver differentiated, novel dual-payload ADCs.”

Jane Chung, Chief Executive Officer of Sutro
4:45 PM ET 10-Q
Financial Results Pimco Capital Solutions BDC Corp.

Pimco Capital Solutions BDC Q3 2026 Results: Turns Profitable, Net Income $3.18M

PIMCO Capital Solutions BDC Corp. reported that non-qualifying assets represented 1.7% of total net assets as of September 30, 2026, down from 3.2% at year-end 2025. The company also disclosed a significant affiliated investment in Voyatek with a fair value of approximately $23.1 million and noted that its credit facility's unused commitment fee expired in June 2026.

Key figure
Net income $3.18M
4:44 PM ET 8-K
Financial Results Spero Therapeutics, Inc. SPRO

Spero Therapeutics Financial Results

Spero Therapeutics reported third quarter 2026 financial results, ending the period with $107.9 million in cash and cash equivalents. The company is focused on advancing its in-licensed anti-CD40L antibody, SP001, toward a Phase 2 trial in IgG4-related disease expected to initiate in Q2 2027.

“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy.”

Esther Rajavelu, President and Chief Executive Officer
4:44 PM ET 10-Q
Financial Results Battalion Oil Corp BATL

Battalion Oil Q3 2026 Results: Net Loss of $43.5M, Loss Widens

Battalion Oil Corp reported total operating revenues of $45.6 million for the quarter ended September 30, 2026, with a net income from operations of $5.0 million. However, the company faced a significant net loss on derivative contracts of $44.8 million during the quarter, compared to a gain in the prior year period.

Key figure
Net loss $43.5M
4:43 PM ET 10-Q
Financial Results Silexion Therapeutics Corp SLXN

Silexion Therapeutics Q3 2026 Results: Net Loss of $2.53M, Loss Narrows

Silexion Therapeutics Corp is a development-stage biotechnology company focused on its Phase 2/3 clinical trial of SIL204 for pancreatic cancer. As of November 12, 2026, the company reported 649,528 ordinary shares outstanding and continues to operate as an emerging growth company with no product revenue to date.

Key figure
Net loss $2.53M
4:43 PM ET 10-Q
Financial Results Innovative Food Holdings Inc IVFH

Innovative Food Holdings Q3 2026 Results: Net Loss of $175K, Loss Narrows

Innovative Food Holdings reported a consolidated net income of $2.03 million for the nine months ended September 30, 2026, a significant recovery from a $2.09 million loss in the prior year period. This improvement was driven by a $1.5 million gain from discontinued operations and a $2.69 million gain on the disposition of assets, despite a decrease in total revenue from $47.3 million to $37.2 million.

Key figure
Net loss $175K
4:43 PM ET 10-Q
Financial Results DiaMedica Therapeutics Inc. DMAC

DiaMedica Therapeutics Q3 2026 Results: Net Loss of $11.3M, Loss Widens

DiaMedica Therapeutics reported a net loss of $31.5 million for the nine months ended September 30, 2026, driven by increased research and development expenses for its lead candidate DM199. The company's cash and marketable securities decreased to $34.9 million from $59.9 million at the end of 2025, reflecting ongoing clinical trial costs for preeclampsia and fetal growth restriction programs.

Key figure
Net loss $11.3M
4:42 PM ET 8-K
Financial Results Laird Superfood, Inc. LSF

Laird Superfood Financial Results

Laird Superfood reported Q3 2026 financial results, featuring a 225% revenue increase to $42.0 million following the acquisitions of Navitas Organics and Terrasoul Superfoods. The company achieved profitability with net income of $1.7 million and Adjusted EBITDA of $2.1 million, driven by acquisition synergies and retail distribution expansion.

Term
Q3 2026

“Q3 was our first full quarter operating Laird Superfood, Navitas Organics, and Terrasoul Superfoods as one platform. Net sales grew 225% to $42.0 million, and Adjusted EBITDA reached $2.1 million as we began capturing synergies. We remain excited by the consumer opportunities in front of us and are increasing our marketing activity to capture and sustain growth from the health and wellness trends that continue to play into the strenghts of our brands. Our new executive team is now in place and, with $17.3 million in cash and no debt, we are well positioned for continued, profitable growth.”

Jason Vieth, Chief Executive Officer
4:42 PM ET 8-K
Financial Results Battalion Oil Corp BATL

Battalion Oil Financial Results

Battalion Oil Corporation reported third quarter 2026 financial results, generating sales volumes of 11,359 Boe/d and total operating revenue of $45.6 million. The company highlighted a significant balance sheet transformation, ending the quarter with $92.1 million in cash and reducing net debt to $70.4 million. Additionally, the company executed a transformative midstream transaction to shift crude transportation from trucking to pipeline, expected to significantly lower gathering costs.

Term
Q3 2026

“Our commitment to operational excellence has shown in our third quarter results. I’m proud of the team and look forward to continued execution”

Daniel Rohling, COO of Battalion
4:42 PM ET 10-Q
Financial Results American Battery Materials, Inc. BLTH

American Battery Materials Q3 2026 Results: Net Loss of $901K, Loss Narrows

American Battery Materials Inc. reported a net loss of $6.09 million for the nine months ended September 30, 2026, driven by significant non-cash expenses related to debt extinguishment and note modifications. The company faces substantial liquidity challenges with a working capital deficit of $13.3 million and only $1,465 in cash, leading to an expressed doubt about its ability to continue as a going concern.

Key figure
Net loss $901K
4:41 PM ET 10-Q
Financial Results Talphera, Inc. TLPH

Talphera Q3 2026 Results: Net Loss of $4.02M, Loss Narrows

For the nine months ended September 30, 2026, Talphera reported a net loss of $10.9 million, compared to a $10.5 million loss in the prior year period. Operating expenses increased to $12.0 million, driven by higher research and development costs related to the Niyad product candidate, while cash and short-term investments totaled $14.2 million.

Key figure
Net loss $4.02M
4:41 PM ET 8-K
Financial Results DiaMedica Therapeutics Inc. DMAC

DiaMedica Therapeutics Financial Results

DiaMedica Therapeutics reported Q3 2026 financial results and provided clinical updates on its DM199 programs. The company completed enrollment in the first two cohorts of its Phase 2 fetal growth restriction (FGR) trial and surpassed the 200-participant enrollment threshold for its ReMEDy2 Phase 2/3 acute ischemic stroke trial, with an interim analysis expected in Q1 2027.

Term
Q3 2026

“During the third quarter and recent weeks, we continued to advance DM199 across each of our clinical programs, including completing enrollment in the first two cohorts of our Phase 2 early-onset fetal growth restriction study and reaching the 200-participant enrollment threshold for the planned interim analysis of ReMEDy2.”

Rick Pauls, President and Chief Executive Officer

“Our clinical programs are providing important opportunities to evaluate the pharmacologic effects of DM199 across pregnancy-related vascular disorders and acute ischemic stroke.”

Julie Krop, MD, Chief Medical Officer
4:40 PM ET 10-Q
Financial Results CapsoVision, Inc CV

CapsoVision Q3 2026 Results: Net Loss of $7.34M, Loss Narrows

CapsoVision reported a net revenue of $10.0 million for the nine months ended September 30, 2026, a slight increase from $9.6 million in the prior year. However, the company experienced a net loss of $21.9 million during this period, driven by high research and development expenses as they pursue FDA clearances for new products like the CapsoCam Colon capsule and AI capabilities.

Key figure
Net loss $7.34M
4:39 PM ET 10-Q
Financial Results T1 Energy Inc. TE

T1 Energy Q3 2026 Results: Net Loss of $40.6M, Loss Narrows

T1 Energy Inc. reported a significant increase in total net sales to $624.4 million for the nine months ended September 30, 2026, driven largely by related party transactions. Despite the revenue growth, the company incurred a net loss of $104.5 million for the period, though this was an improvement from the $178.7 million loss in the prior year.

Key figure
Net loss $40.6M
4:39 PM ET 10-Q
Financial Results Blackstone Private Credit Fund BCRED

Blackstone Private Credit Fund Q3 2026 Results: Net Income $704M, Down 12.5% YoY

As of September 30, 2026, Blackstone Private Credit Fund reported total assets of $79.1 billion and total net assets of $41.1 billion, reflecting a decrease from $47.6 billion at year-end 2025. The fund's investment portfolio is primarily composed of non-controlled/non-affiliated investments valued at $71.3 billion, supported by $34.2 billion in debt.

Key figure
Net income $704M · -12.5% YoY
4:39 PM ET 8-K
Financial Results Dillard's, Inc. DDS

Dillard's Financial Results

Dillard's reported Q3 2026 net income of $130.9 million, or $8.38 per share, on total retail sales of $1.418 billion. The company achieved 1% comparable store sales growth and maintained a strong retail gross margin of 45.3%.

Term
Q3 2026

“We achieved 1% sales growth on top of last year’s 3% increase, supporting a strong 45.3% retail gross margin. As we head into the holidays, our stores and dedicated team are ready to welcome and serve our customers.”

William T. Dillard, II, Chief Executive Officer
4:39 PM ET 10-Q
Financial Results Nakamoto Inc. NAKA

Nakamoto Q3 2026 Results: Turns Profitable, Net Income $85.5M

Nakamoto Inc. reported a net income of $85.5 million for the quarter ended September 30, 2026, a significant recovery from an $86.0 million loss in the prior year, primarily driven by a $110.4 million gain on the fair value of digital assets. However, the company faces a year-to-date net loss of $286.2 million due to substantial goodwill impairment and non-operating expenses earlier in the year.

Key figure
Net income $85.5M
4:39 PM ET 10-Q
Financial Results NeuroPace Inc NPCE ▶ Call

NeuroPace Q3 2026 Results: Net Loss of $3.3M, Loss Narrows

NeuroPace reported a decrease in total assets from $105.6 million at the end of 2025 to $94.8 million as of September 30, 2026, primarily driven by a reduction in cash and short-term investments. The company maintains a significant accumulated deficit of $568.6 million and expects to lose its emerging growth company status on December 31, 2026.

Key figure
Net loss $3.3M
4:38 PM ET 10-Q
Financial Results Gaxos.Ai Inc. GXAI

Gaxos.Ai Q3 2026 Results: Net Loss of $930K, Loss Narrows

GAXOS.AI INC. reported a significant revenue increase to $7.08 million for the nine months ended September 30, 2026, compared to $0.69 million in the prior year, driven by a $1.75 million gain on the sale of gaming assets. Despite the revenue growth, the company incurred a net loss attributable to common shareholders of $2.86 million due to a substantial rise in selling, general, and administrative expenses.

Key figure
Net loss $930K

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.